Home  >  News
Patents + Font Resize -

PTAB upholds Medac Pharma's patents on Rasuvo

Monday, February 12, 2018, 17:00 Hrs  [IST]

Medac Pharma, Inc., a privately held pharmaceutical company, announced the Patent Trial And Appeal Board (PTAB) has upheld all 22 claims of our parent company medac GmbH's patent covering its rheumatoid arthritis treatment, Rasuvo, an auto-injector that provides highly concentrated doses of methotrexate.  This ruling ends the challenge brought by Koios Pharmaceuticals LLC.

"Medac is gratified by the PTAB decision upholding the patentability of all the claims of its '231 patent," stated Medac's CEO Terri Shoemaker. "The patent, which is based on Medac's pioneering work to bring methotrexate treatment to patients in need of safe, less painful, and easy to use form, does not expire until 2029.

Medac Pharma, Inc. is a privately held specialty pharmaceutical company focused on the development, in-licensing and commercialization of late-stage molecules. Medac Pharma is the wholly-owned subsidiary of medac GmbH, a well-known and respected global pharmaceutical company that has been making scientific and therapeutic discoveries for more than 40 years. 


* Name :     
* Email :    
  Website :  
Copyright © 2016 Saffron Media Pvt. Ltd |